1. Home
  2. ETON vs GLU Comparison

ETON vs GLU Comparison

Compare ETON & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eton Pharmaceuticals Inc.

ETON

Eton Pharmaceuticals Inc.

HOLD

Current Price

$16.81

Market Cap

498.8M

Sector

Health Care

ML Signal

HOLD

Logo Gabelli Global Utility of Beneficial Ownership

GLU

Gabelli Global Utility of Beneficial Ownership

HOLD

Current Price

$19.81

Market Cap

116.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETON
GLU
Founded
2017
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
498.8M
116.8M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ETON
GLU
Price
$16.81
$19.81
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$29.67
N/A
AVG Volume (30 Days)
233.1K
12.4K
Earning Date
11-06-2025
01-01-0001
Dividend Yield
N/A
8.60%
EPS Growth
N/A
N/A
EPS
N/A
0.62
Revenue
$70,316,000.00
N/A
Revenue This Year
$107.23
N/A
Revenue Next Year
$29.72
N/A
P/E Ratio
N/A
$22.50
Revenue Growth
102.77
N/A
52 Week Low
$11.09
$11.61
52 Week High
$23.00
$15.40

Technical Indicators

Market Signals
Indicator
ETON
GLU
Relative Strength Index (RSI) 51.87 66.30
Support Level $16.27 $18.36
Resistance Level $17.33 $20.13
Average True Range (ATR) 0.64 0.27
MACD 0.15 0.13
Stochastic Oscillator 66.14 64.59

Price Performance

Historical Comparison
ETON
GLU

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

Share on Social Networks: